The main objective of the project is to validate the uremic biomarkers in a clinical research setting by developing a diagnostic medical device in the form of a novel on-line dialysis sensor that offers a unique method for the biomarker detection
• Business plan –preparing a thorough business plan to determine the best commercialization strategy for the technology concerning possible product diversification options. This requires conducting a market study, risk assessment, financial analysis including the need for further investments from private funds (Angel Investors, VCs, and industry partners).
• IPR strategy – by updating the freedom-to-operate study and relying on market information on the most important markets the patent strategy will be finalized. This will feed valuable input to business related activities as IP strategy and commercialization plan are tightly linked by determining the market entry strategy.
• Technological configuration – defining the technical configurations for possible product diversification: 1) high-end MCM monitor, incorporating technology for monitoring all groups of uremic biomarkers, 2) low-end MCM monitor, incorporating technology for monitoring limited/selected groups of uremic biomarkers. The high-end MCM monitors could be applicable during the advanced therapies and in critical situations like patients needing highly personalized treatment or in the Intensive Care Units. Low-end MCM monitors could be utilized during ESRD treatments with standard clinical settings in large patient centres. The evaluation of the market potential, customer segments and commercialization strategy of adding a low-end monitor in the product line and having two configuration options instead of one will be performed under business related activities.
